Anti-Guanine Deaminase (GDA) Rabbit Polyclonal Antibody for WB, ELISA - Q9Y2T3

Core Product Specifications and Parameters

Biological Background: Guanine Deaminase Function and Localization

• Guanine deaminase (GDA), also designated guanine aminohydrolase (GAH) or p51-nedasin, is encoded by the GDA gene (KIAA1258) and belongs to the guanine deaminase family.
• The enzyme catalyzes the hydrolytic deamination of guanine, converting it to xanthine and ammonia, a critical step in purine metabolism and nitrogen recycling.
• GDA is a zinc-dependent hydrolase, with metal-binding domains essential for its catalytic activity.
• Keywords from UniProt indicate that the protein undergoes alternative splicing and phosphorylation, suggesting multiple isoforms and regulatory post-translational modifications.
• A 3D-structure is available for GDA, providing insights into its substrate specificity and catalytic mechanism.
• GDA has been identified through proteomics studies, confirming its endogenous expression in multiple tissues.

Experimental Guidance and Technical Tips

• The immunogen spans the central region (amino acids 165-454) of human GDA, so the antibody may recognize both full-length and certain truncated isoforms; verify in your specific model system.
• For Western blotting, a band around 51 kDa is expected; include positive controls from human, mouse, or rat cell lysates known to express GDA.
• In ELISA applications, consider the antigen presentation format; the antibody may perform differently in direct vs. sandwich assays.
• As a polyclonal antibody, lot-to-lot consistency may vary; pre-validate each new lot with appropriate controls.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is dedicated to providing diagnostic manufacturers, laboratories, and research institutions with a seamless supply of high-quality IVD raw materials. Our anti-GDA rabbit polyclonal antibody supports studies into purine metabolism disorders and related research areas. Beyond individual antibodies, CamelBio offers validated antibody pairs, bulk quantities of monoclonal/polyclonal antibodies, ancillary reagents, and custom rare target sourcing to accelerate your project from concept to clinic.